Scholar Rock Holding Corp

NASDAQ:SRRKUnited States

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.

Contact Information

Headquarters

301 BINNEY STREET, 3RD FLOORCAMBRIDGE, MA, United States 02142

Phone

857-259-3860

Fax

302-655-5049

Executives

Independent Chairman of the Board

David Hallal

President, Chief Executive Officer, Director

Jay Backstrom

Chief Financial Officer, Chief Operating Officer

Edward Myles

Chief Human Resource Officer

Caryn Parlavecchio

Chief Scientific Officer

Mo Qatanani